V

Velocity Clinical Research | Clinical Research Institute of Southern Oregon (CRISOR)

Research site
(Unclaimed)
Location
3860 Crater Lake Avenue, Medford, Oregon, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

9 of 10
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Placebo
Drug: Rezpegaldesleukin

The coprimary objectives of the study are to:evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineu...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The primary objectives of this study are to:estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus re...

Active, not recruiting
Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Enrolling
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

This study is being conducted to evaluate RGT001-075 to help people who are above a healthy weight range to lose weight. In this study participants w...

Enrolling
Obesity
Drug: RGT001-075
Drug: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: CIN-102 Dose 1
Drug: CIN-102 Dose 2

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

Trial conditions

Atopic Dermatitis (4 trials)
Dermatitis (4 trials)
Eczema (4 trials)
Obesity (2 trials)
Asthma (1 trial)
Cough (1 trial)
Gastroparesis (1 trial)
Hypertriglyceridemia (1 trial)
Overweight (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems